Abcam launches SimpleStep Ignite ELISA

13/04/2026

An innovative assay platform that combines 50x higher sensitivity and up to 35x wider dynamic range in only 55 minutes

Cambridge, UK – April 13, 2026 – Abcam today announced SimpleStep Ignite™ ELISA, a next generation chemiluminescent immunoassay platform designed for scientists who need faster and higher quality decisions without compromising data integrity.

Delivering results in 55 minutes – up to 6× faster than traditional colorimetric ELISAs, SimpleStep Ignite™ combines 50× greater sensitivity with an up to 35× broader measuring range to quantify low abundance and high abundance targets in a single, streamlined workflow.

In an environment where research timelines are tight and sample volumes are precious; assay performance has become a critical rate-limiting step. SimpleStep Ignite™ ELISA is built to help scientists increase daily data output, reduce reruns, and move from results to decision faster with robust sensitivity, a wide dynamic range, and reproducibility that supports confident decision-making across discovery and preclinical workflows.

“The pace of scientific progress is increasingly defined by how quickly researchers can turn complex data into confident decisions. At Abcam, we believe advancing science means removing the barriers that slow discovery as ambition and complexity grow. SimpleStep Ignite™ reflects that belief, bringing together speed, performance, and scalable simplicity to help scientists generate trusted insights faster and sustain momentum in pursuit of the questions that matter most.” Markus Lusser, President, Abcam

SimpleStep Ignite™ combines chemiluminescent detection with Abcam’s optimized SimpleStep^® technology to deliver stronger signal, lower background, and consistent quantification, without additional workflow complexity. Each kit is built using optimized antibody pairs to support consistent batch-to-batch performance and reproducible results across complex biological matrices including serum, plasma, urine, cerebrospinal fluid (CSF), and more.

With fewer incubations and a simple single wash protocol, researchers can quantify both high and low-abundance targets with the same kit, reducing repeat work, extra dilutions, and sample consumption. The standardized workflow supports plate by plate studies as well as higher throughput screening, enabling teams scale data generation without sacrificing quality.

According to Robert Zawada, Sr. Director Product Development at PrognomiQ, SimpleStep Ignite™ ELISA delivers the performance his team needs:“We originally chose SimpleStep^® ELISA for its efficiency and ease of use. As our projects grow in scale and complexity, we need even greater performance. The new SimpleStep Ignite™ version delivers the broad performance range we require, allowing us to measure our samples with a streamlined approach without disrupting our established workflows.”